NCT01877109 (SMC-LCS-II) is a clinical trial in Lymphoma, sponsored by Samsung Medical Center.

Who is sponsoring NCT01877109?

NCT01877109 is sponsored by Samsung Medical Center.

Is NCT01877109 still recruiting?

NCT01877109 is currently completed. Last updated 27 October 2017.

Last reviewed 2017-10-27 · How we verify

NCT01877109: SMC-LCS-II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Samsung Medical Center-Lymphoma Cohort Study-II

Completed Last updated 27 October 2017

What this trial tests

trial in Lymphoma in 1,358 participants. Completed in 28 February 2017.

Timeline

1 February 2012

Primary endpoint
28 February 2017

28 February 2017

Quick facts

Lead sponsor	Samsung Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,358
Start date	1 February 2012
Primary completion	28 February 2017
Estimated completion	28 February 2017
Sites	1 location across South Korea

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Samsung Medical Center

Who can join

19 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I, Lee H, Yoon SE, Ryu KJ, et al · · 2020 · cited 32× · PMID 32054467 · DOI 10.1186/s12885-020-6612-2
The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma.
Ham JS, Kim SJ, Choi JY, Hyun SH, et al · · 2016 · cited 11× · PMID 26871713 · DOI 10.1038/bcj.2016.2
A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score.
Yhim HY, Eshet Y, Metser U, Lim CH, et al · · 2020 · cited 6× · PMID 33216888 · DOI 10.1182/bloodadvances.2020002814
Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia.
Cho JH, Shim JH, Yoon SE, Kim HJ, et al · · 2021 · cited 4× · PMID 32791817 · DOI 10.3904/kjim.2019.367

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01877109 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 27 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01877109.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing